Paradoxical Autoinflammatory Skin Reaction to Tumor Necrosis Factor Alpha Blockers Manifesting as Amicrobial Pustulosis of the Folds in Patients with Inflammatory Bowel Diseases

Medicine (United States)

Volumn 94, Issue 45, 2015, Pages e1818-

  Marzano, Angelo V ^a   Tavecchio, Simona ^b   Berti, Emilio ^a   Gelmetti, Carlo ^a   Cugno, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMOXICILLIN; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CLAVULANIC ACID; CLOBETASOL PROPIONATE; CXCL1 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; GELATINASE A; GELATINASE B; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 8; L SELECTIN; METHYLPREDNISOLONE; PREDNISONE; PSEUDOMONIC ACID; RANTES; SALAZOSULFAPYRIDINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; USTEKINUMAB; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

ACANTHOSIS; ADULT; AMICROBIAL PUSTULOSIS OF THE FOLD; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; CROHN DISEASE; DRUG DOSE REDUCTION; EXTERNAL AUDITORY CANAL; FEMALE; FOLLOW UP; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; INFLAMMATORY INFILTRATE; INGUINAL REGION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTIC INFILTRATION; MAINTENANCE DRUG DOSE; MALE; NEUTROPHILIC INFLAMMATORY INFILTRATION; PARADOXICAL AUTOINFLAMMATORY SKIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUSTULE; PUSTULOSIS; RELAPSE; REMISSION; SKIN BIOPSY; SKIN EDEMA; SKIN MANIFESTATION; SKINFOLD; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SUPERINFECTION; TREATMENT RESPONSE; ULCERATIVE COLITIS; DRUG ERUPTIONS; INFLAMMATORY BOWEL DISEASES; PATHOLOGY;

ADALIMUMAB; ADULT; ANTI-INFLAMMATORY AGENTS; DRUG ERUPTIONS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE;

EID: 84958166254     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001818     Document Type: Article

References (34)

1. Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;3:13.
2. Burgdorf W. Cutaneous manifestations of Crohn's disease. J Am Acad Dermatol. 1981;5:689-695.
3. Palamaras I, El-Jabbour J, Pietropaolo N, et al. Metastatic Crohn's disease: a review. J Eur Acad Dermatol Venereol. 2008;22:1033-1043.
4. Timani S, Mutasim DF. Skin manifestations of inflammatory bowel disease. Clin Dermatol. 2008;26:265-273.
5. Marzano AV, Borghi A, Stadnicki A, et al. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20:213-227.
6. Marzano AV, Borghi A, Meroni PL, et al. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity. 2014;47:146-153.
7. Lee HY, Pelivani N, Beltraminelli H, et al. Amicrobial pustulosislike rash in a patient with Crohn's disease under anti-TNF-alpha blocker. Dermatology. 2011;222:304-310.
8. Marzano AV, Capsoni F, Berti E, et al. Amicrobial pustular dermatosis of cutaneous folds associated with autoimmune disorders: a new entity? Dermatology. 1996;193:88-93.
9. Marzano AV, Ramoni S, Caputo R. Amicrobial pustulosis of the folds. Dermatology. 2008;216:305-311.
10. Wallach D, Vignon-Pennamen M-D. From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research. J Am Acad Dermatol. 2006;55:1066-1071.
11. Lagrange S, Chosidow O, Piette JC, et al. A peculiar form of amicrobial pustulosis of the folds associated with systemic lupus erythematosus and other auto-immune diseases. Lupus. 1997;6:514-520.
12. Vignon-Pennamen MD, Wallach D. Cutaneous manifestations of neutrophilic disease. Dermatologica. 1991;183:255-264.
13. Bénéton N, Wolkenstein P, Bagot M, et al. Amicrobial pustulosis associated with autoimmune diseases: healing with zinc supplementation. Br J Dermatol. 2000;143:1306-1310.
14. Kuyama M, Fujimoto W, Kambara H, et al. Amicrobial pustular dermatosis in two patients with immunological abnormalities. Clin Exp Dermatol. 2002;27:286-289.
15. Hoch O, Herbst RA, Gutzmer R, et al. Amicrobial intertriginous pustulosis in autoimmune disease: a new entity? Hautarzt. 1998;49:634-640.
16. Natsuga K, Sawamura D, Homma E, et al. Amicrobial pustulosis associated with IgA nephropathy and Sjögren's syndrome. J Am Acad Dermatol. 2007;57:523-526.
17. Marzano AV, Ishak RS, Saibeni S, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013;45:202-210.
18. Doria A, Zen M, Bettio S, et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev. 2012;12:22-30.
19. Marzano AV, Fanoni D, Antiga E, et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. Clin Exp Immunol. 2014;178:48-56.
20. Dinarello CA. A clinical perspective of IL-1ß as the gatekeeper of inflammation. Eur J Immunol. 2011;41:1203-1217.
21. Oppenheim JJ, Zachariae CO, Mukaida N, et al. Properties of the novel proinflammatory supergene 'intercrine' cytokine family. Ann Rev Immunol. 1991;9:617-648.
22. Marzano AV, Cugno M, Trevisan V, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol. 2010;162:100-107.
23. Pene J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008;180:7423-7430.
24. Dardalhon V, Korn T, Kuchroo VK, et al. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun. 2008;31:252-256.
25. Nalbandian A, Crispin JC, Tsokos GC. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol. 2009;157:209-215.
26. Ruddy MJ, Wong GC, Liu XK, et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem. 2004;279:2559-2567.
27. Agarwal S, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol. 2008;35:515-519.
28. Delclaux C, Delacourt C, D'Ortho MP, et al. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol. 1996;14:288-295.
29. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereeol. 2009;23:1-70.
30. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202:135-143.
31. Guerra I, Algaba A, Perez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6:518-523.
32. Denadai R, Teixeira VF, Saad-Hossne R. Letter: pathogenesis of tumor necrosis factor alpha antagonists-induced psoriasiform lesions. Aliment Pharmacol Ther. 2012;36:77-78.
33. Iborra M, Beltran B, Bastida G, et al. Infliximab and adalimumabinduced psoriasis in Crohn's disease: a paradoxical side effect. J Crohns Colitis. 2011;5:157-161.
34. Rahier JF, Buche S, Peyrin-Biroulet L. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroeneterol Hepatol. 2010;8:1048-1055.